← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue increased 18.8% to $5.03B, while Net income increased 15.4% to $344.0M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $5.03BOK
- Profitability — Net income $344.0MOK
- Cash generation — Free cash flow N/ANote
- Accounting — Formula-grey distress score · no manipulation flag · earnings quality safeNote
- Insiders — 0 buys; 31 sells in 365 daysNote
- Capital — dividends paid were $14.4M; share repurchases were $20.0MNote
Business
ENSIGN GROUP, INC: All of our independent subsidiaries, the Service Center (defined below) and our wholly-owned captive insurance subsidiary (the Captive Insurance) and captive real estate investment trust called Standard Bearer Healthcare REIT, Inc.
Where the revenue comes from
Fiscal 2025, as ENSIGN GROUP, INC reports it. History and quarterly detail are in the app.
- Skilled Services$4.8B
- Standard Bearer$126.9M
Leadership changes
From ENSIGN GROUP, INC's own filings, the day they're filed.
- Barry Port · Chair · appointmenteff. 2025-09-01
- Christopher Christensen · Directors · departureeff. 2025-09-01
- Marivic S. Uychiat · departureeff. 2025-09-01
Latest filings
- 8-K · Company announcement2026-08-25
- 8-K · Company announcement2026-08-20
- 10-Q · Quarterly report2026-07-27
- 8-K · Company announcement2026-07-27
- 8-K · Company announcement2026-06-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ENSIGN GROUP, INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.